Company intelligence / Profile preview

Sound Wave Innovation

Chuo-ku, Tokyo, Japansw-innovation.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Sound Wave Innovation has reached target enrollment in a pivotal trial of its LIPUS device for early Alzheimer’s disease. Its LIPUS-Brain medical device was designated as an Eligible Product under Japan's Breakthrough Medical Device Designation Program in 2024. Clinical studies are ongoing, and recent publications and awards highlight progress in both preclinical and clinical research.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceNon-pharmacological therapy (Low-intensity pulsed ultrasound)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

LIPUS-Brain

Phase 3

Indications: Alzheimer's disease

1 more asset in the full pipeline.

Request access →

Partnerships

Strong relationship with Tohoku University; no major pharma partnerships disclosed

Beyond the preview

Go deeper on Sound Wave Innovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sound Wave Innovation.

Explore the full profile